SCYX SCYNEXIS Inc Forecast, Technical & Fundamental Analysis
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs... Show more
SCYX is expected to report earnings to fall 82.64% to -58 cents per share on November 11
Q3'26
Est.
$-0.58
Q1'26
Missed
by $2.32
Q4'25
Beat
by $0.12
Q3'25
Beat
by $0.03
Q2'25
Beat
by $0.06
The last earnings report on May 11 showed earnings per share of -335 cents, missing the estimate of -103 cents. With 19.70K shares outstanding, the current market capitalization sits at 50.74M.
A.I. Advisor
published General Information
General Information
a company which engages in discovery, development and commercialization of novel anti infectives
A.I.dvisor tells us that SCYX and ACET have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCYX and ACET's prices will move in lockstep.
SCYX's RSI Oscillator recovers from overbought zone
The 10-day RSI Indicator for SCYX moved out of overbought territory on August 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 46 cases where SCYX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on August 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SCYX as a result. In of 73 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCYX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
SCYX broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for SCYX just turned positive on July 31, 2026. Looking at past instances where SCYX's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .
SCYX moved above its 50-day moving average on July 31, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SCYX crossed bullishly above the 50-day moving average on August 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SCYX advanced for three days, in of 226 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 98 cases where SCYX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.758) is normal, around the industry mean (40.756). P/E Ratio (0.905) is within average values for comparable stocks, (94.098). SCYX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.238). SCYX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (2.043) is also within normal values, averaging (177.108).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SCYX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SCYX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
